Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02229864
Registration number
NCT02229864
Ethics application status
Date submitted
9/06/2014
Date registered
3/09/2014
Date last updated
12/03/2021
Titles & IDs
Public title
Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions
Query!
Scientific title
ABSORB III RCT Pharmacokinetics (PK) Sub-study
Query!
Secondary ID [1]
0
0
10-392 B
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Coronary Artery Stenosis
0
0
Query!
Coronary Disease
0
0
Query!
Coronary Stenosis
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Coronary artery stenting: Absorb BVS
Experimental: Coronary artery stenting: Absorb BVS - Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
Treatment: Devices: Coronary artery stenting: Absorb BVS
Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Maximum Concentration (Cmax)
Query!
Assessment method [1]
0
0
Maximal observed blood analyte concentration. Cmax is the highest blood everolimus concentration reached during the 30 day period of the study after assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation).
Query!
Timepoint [1]
0
0
0 to 30 days
Query!
Primary outcome [2]
0
0
Time of Maximum (Tmax)
Query!
Assessment method [2]
0
0
Time to reach the maximal observed blood analyte concentration during the 30 day period of the study after assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation).
Query!
Timepoint [2]
0
0
0 to 30 days
Query!
Primary outcome [3]
0
0
AUC24h
Query!
Assessment method [3]
0
0
Area under the blood analyte concentration vs. time curve from time 0 up to 24 hours post placement of the last Absorb BVS. Calculated by the Lin Up Log Down trapezoidal method.
Query!
Timepoint [3]
0
0
0 to 24 hours
Query!
Primary outcome [4]
0
0
AUC Last
Query!
Assessment method [4]
0
0
Area under the blood analyte concentration vs. time curve from time 0 up to the last quantifiable concentration reached during the 30 day period of the study. After assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation). Calculated by the Lin Up Log Down trapezoidal method.
Query!
Timepoint [4]
0
0
0 to 30 days
Query!
Primary outcome [5]
0
0
AUC 0-infinity
Query!
Assessment method [5]
0
0
AUC 0-infinity: Area under the blood analyte concentration vs. time curve from time zero and extrapolated to infinite time, reached during the 30 day period of the study. After assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation).
calculated as: AUC0-8 = AUClast + (Clast/?z)
The percentage of AUC0-8 obtained by extrapolation (%AUC0-8ex) is calculated as:
%AUC0-8ex = (AUC0-8 - AUClast)/ AUC0-8 * 100
Query!
Timepoint [5]
0
0
0 to 30 days
Query!
Primary outcome [6]
0
0
Terminal Elimination Rate Constant (?z)
Query!
Assessment method [6]
0
0
The apparent terminal elimination rate constant during the 30 day period of the study. After assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation). Determined by linear regression of terminal points of the ln-linear analyte concentration-time curve.
Query!
Timepoint [6]
0
0
0 to 30 days
Query!
Primary outcome [7]
0
0
Terminal Elimination Half-life (t1/2term)
Query!
Assessment method [7]
0
0
The apparent terminal elimination half-life, reached during the 30 day period of the study. After assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation).
calculated as: t1/2term = 0.693/?z.
Query!
Timepoint [7]
0
0
0 to 30 days
Query!
Primary outcome [8]
0
0
Drug Clearance (CL)
Query!
Assessment method [8]
0
0
The systemic drug clearance, reached during the 30 day period of the study. After assessing at different time frames (10 minutes, 30 minutes, 1 hr, 2 hrs, 4 hrs, 6 hrs , 12 hrs, 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 14 days, and 30 days post implantation).
Calculated as: CL = Dose/AUC0 - 8 .
Query!
Timepoint [8]
0
0
0 to 30 days
Query!
Secondary outcome [1]
0
0
Number of Participants With Target Lesion Failure (TLF)
Query!
Assessment method [1]
0
0
Target Lesion Failure (TLF) includes Cardiac Death, Target vessel - myocardial infarction and Target Lesion Revascularization (TLR).
Query!
Timepoint [1]
0
0
0 to 1853 Days
Query!
Secondary outcome [2]
0
0
Number of Participants With All Death
Query!
Assessment method [2]
0
0
All death includes cardiac death, vascular death, and non-cardiac death.
Query!
Timepoint [2]
0
0
0 to 1853 Days
Query!
Secondary outcome [3]
0
0
Number of Participants With All Myocardial Infarction (MI)
Query!
Assessment method [3]
0
0
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI).
Query!
Timepoint [3]
0
0
0 to 1853 Days
Query!
Secondary outcome [4]
0
0
Number of Participants With All Target Lesion Revascularization (TLR)
Query!
Assessment method [4]
0
0
All target lesion revascularization includes ischemia-driven target lesion revascularization (ID-TLR) and non ischemia-driven target lesion revascularization (NID-TLR).
Query!
Timepoint [4]
0
0
0 to 1853 Days
Query!
Secondary outcome [5]
0
0
Number of Participants With All Target Vessel Revascularization (TVR)
Query!
Assessment method [5]
0
0
All target vessel revascularization includes ischemia driven target vessel revascularization (ID-TVR) and non ischemia driven target vessel revascularization (NID-TVR).
Query!
Timepoint [5]
0
0
0 to 1853 Days
Query!
Secondary outcome [6]
0
0
Number of Participants With All Revascularization
Query!
Assessment method [6]
0
0
All revascularization includes ischemia driven revascularization and non ischemia driven revascularization.
Query!
Timepoint [6]
0
0
0 to 1853 Days
Query!
Secondary outcome [7]
0
0
Number of Participants With Acute Stent/Scaffold Thrombosis (Definite/Probable)
Query!
Assessment method [7]
0
0
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation
Query!
Timepoint [7]
0
0
= 1 day
Query!
Secondary outcome [8]
0
0
Number of Participants With Subacute Stent/Scaffold Thrombosis (Definite/Probable)
Query!
Assessment method [8]
0
0
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation
Query!
Timepoint [8]
0
0
>1 to 30 days
Query!
Secondary outcome [9]
0
0
Number of Participants With Late Stent/Scaffold Thrombosis (Definite/Probable)
Query!
Assessment method [9]
0
0
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation
Query!
Timepoint [9]
0
0
31 to 393 days
Query!
Secondary outcome [10]
0
0
Number of Participants With Cumulative Stent/Scaffold Thrombosis (Definite/Probable)
Query!
Assessment method [10]
0
0
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: >24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: >1 year post stent implantation
Query!
Timepoint [10]
0
0
0 to 1853 Days
Query!
Eligibility
Key inclusion criteria
General
1. 18 years of age.
2. Subject or a legally authorized representative must provide written Informed Consent
prior to any study related procedure, per site requirements.
3. Evidence of myocardial. In the absence of noninvasive ischemia, FFR must be done and
indicative of ischemia.
4. An acceptable candidate for coronary artery bypass graft (CABG) surgery.
5. Female subject of childbearing potential who does not plan pregnancy for up to 1 year
following the index procedure.
6. Female subject is not breast-feeding at the time of the screening visit and will not
be breast-feeding for up to 1 year following the index procedure.
7. Subject agrees to not participate in any other investigational or invasive clinical
study for a period of 1 year following the index procedure.
Angiographic
1. One or two de novo target lesions:
1. If two target lesions are present, they must be present in different epicardial
vessels and both must satisfy the angiographic eligibility criteria.
2. The definition of epicardial vessels means the left anterior descending (LAD),
left coronary artery (LCX), and right coronary artery (RCA) and their branches.
Thus, the patient must not have lesions requiring treatment in e.g. both the LAD
and a diagonal branch.
2. Target lesion(s) must be located in a native coronary artery with a visually estimated
or quantitatively assessed % diameter stenosis (DS) of = 50% and < 100% with a
thrombolysis in myocardial infarction (TIMI) flow of = 1 and one of the following:
stenosis = 70%, an abnormal functional test (e.g., fractional flow reserve (FFR),
stress test), unstable angina or post-infarct angina.
1. Lesion(s) must be located in a native coronary artery with reference vessel
diameter (RVD) by visual estimation of = 2.50 mm and = 3.75 mm.
2. Lesion(s) must be located in a native coronary artery with length by visual
estimation of = 24 mm.
General
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or an
Adenosine diphosphate receptor (ADP) antagonist is planned within 12 months after the
procedure.
2. Subject has known hypersensitivity or contraindication to device material and its
degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid) and
cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot
be adequately pre-medicated. Subject has a known contrast sensitivity that cannot be
adequately pre-medicated.
3. Subject has known allergic reaction, hypersensitivity or contraindication to aspirin;
or to clopidogrel and prasugrel and ticagrelor; or to heparin and bivalirudin, and
therefore cannot be adequately treated with study medications.
4. Subject had an acute myocardial infarction (AMI: STEMI or NSTEMI) within 72 hours of
the index procedure and both creatine kinase (CK) and creatine kinase myocardial-band
isoenzyme (CK-MB) have not returned to within normal limits at the time of index
procedure; or subject with stable angina or silent ischemia has CK-MB that is greater
than normal limits at the time of the index procedure.
5. Subject is currently experiencing clinical symptoms consistent with new onset AMI
(STEMI or NSTEMI), such as nitrate-unresponsive prolonged chest pain with ischemic ECG
changes.
6. Subject has a cardiac arrhythmia as identified at the time of screening for which at
least one of the following criteria is met:
1. Subject requires coumadin or any other agent for chronic oral anticoagulation
2. Subject is likely to become hemodynamically unstable due to their arrhythmia
3. Subject has poor survival prognosis due to their arrhythmia
7. Subject has a left ventricular ejection fraction (LVEF) < 30%
8. Subject has undergone prior percutaneous coronary intervention (PCI) within the target
vessel(s) during the last 12 months.
9. Subject requires future staged PCI either in target or non-target vessels or subject
requires future peripheral interventions < 30 days after the index procedure.
10. Subject has received any solid organ transplants or is on a waiting list for any solid
organ transplants.
11. At the time of screening, the subject has a malignancy that is not in remission.
12. Subject is receiving immunosuppressant therapy or has known immunosuppressive or
severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human
immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are
not included as immunosuppressant therapy.
13. Subject has previously received or is scheduled to receive radiotherapy to a coronary
artery (vascular brachytherapy), or the chest/mediastinum.
14. Subject is receiving or will require chronic anticoagulation therapy (e.g., coumadin,
dabigatran, apixaban, rivaroxaban or any other agent for any reason).
15. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3.
16. Subject has a documented or suspected hepatic disorder as defined as cirrhosis or
Child-Pugh = Class B.
17. Subject has renal insufficiency as defined as an estimated glomerular filtration rate
(GFR) < 30 ml/min/1.73m2 or dialysis at the time of screening.
18. Subject is high risk of bleeding for any reason; has a history of bleeding diathesis
or coagulopathy; has had a significant gastro-intestinal or significant urinary bleed
within the past six months.
19. Subject has had a cerebrovascular accident or transient ischemic neurological attack
(TIA) within the past six months, or any prior intracranial bleed, or any permanent
neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous
malformation, etc.).
20. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath
insertion. Note: femoral arterial disease does not exclude the patient if radial
access may be used.
21. Subject has life expectancy < 5 years for any non-cardiac cause or cardiac cause.
22. Subject is in the opinion of the Investigator or designee, unable to comply with the
requirements of the study protocol or is unsuitable for the study for any reason.
23. Subject is currently participating in another clinical trial that has not yet
completed its primary endpoint.
24. Subject is part of a vulnerable population
Angiographic
All exclusion criteria apply to the target lesion(s) or target vessel(s).
1. Lesion which prevents successful balloon pre-dilatation
2. Lesion is located in left main.
3. Aorto-ostial RCA lesion.
4. Lesion located within 3 mm of the origin of the LAD or LCX.
5. Lesion involving a bifurcation with a:
1. side branch = 2 mm in diameter, or
2. side branch with either an ostial or non-ostial lesion with diameter stenosis >
50%, or
3. side branch requiring dilatation.
6. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS.
7. Vessel contains thrombus as indicated in the angiographic images or by intravascular
ultrasound (IVUS) or optical coherence tomography (OCT).
8. Lesion or vessel involves a myocardial bridge.
9. Vessel has been previously treated with a stent at any time prior to the index
procedure such that the Absorb BVS would need to cross the stent to reach the target
lesion.
10. Vessel has been previously treated and the target lesion is within 5 mm proximal or
distal to a previously treated lesion.
11. Target lesion located within an arterial or saphenous vein graft or distal to any
arterial or saphenous vein graft.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
12
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Michigan
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Abbott Medical Devices
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The ABSORB III PK sub-study is a prospective, open-label, non-blinded study enrolling
approximately 12 subjects in up to 5 US sites. ABSORB III PK sub-study is a part of ABSORB
III RCT (NCT01751906). The objective is to determine the pharmacokinetics of everolimus
delivered by the Absorb BVS in a separate and non-randomized cohort of subjects who only
receive Absorb BVS with a maximum of two de novo native coronary artery lesions after
implantation of the Absorb BVS.
Note: The ABSORB III PK subjects will not contribute to the determination of the ABSORB III
RCT primary endpoint.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02229864
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
David G. Rizik, MD
Query!
Address
0
0
Scottsdale Healthcare, Scottsdale, AZ
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02229864
Download to PDF